Welcome to Awesome Blog Design perfect blog
Business, Healthcare

Bristol Myers Squibb presents late-breaking Phase 2 data demonstrating the safety and efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints Deucravacitinib was well-tolerated with